Hl Financial Services buys $14,989,684 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Hl Financial Services scooped up 3,971 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 343,249 shares of Abbott Laboratories which is valued at $14,989,684.Abbott Laboratories makes up approximately 0.35% of Hl Financial Services’s portfolio.

Other Hedge Funds, Including , Parthenon reduced its stake in ABT by selling 507 shares or 1.03% in the most recent quarter. The Hedge Fund company now holds 48,552 shares of ABT which is valued at $2,120,266. Abbott Laboratories makes up approx 0.52% of Parthenon’s portfolio.A. D. Beadell Investment Counsel boosted its stake in ABT in the latest quarter, The investment management firm added 10,475 additional shares and now holds a total of 51,878 shares of Abbott Laboratories which is valued at $2,239,573. Abbott Laboratories makes up approx 1.79% of A. D. Beadell Investment Counsel’s portfolio.Boyd Watterson Asset Managementoh boosted its stake in ABT in the latest quarter, The investment management firm added 2,295 additional shares and now holds a total of 40,981 shares of Abbott Laboratories which is valued at $1,724,890. Abbott Laboratories makes up approx 0.83% of Boyd Watterson Asset Managementoh’s portfolio.

Abbott Laboratories opened for trading at $44.38 and hit $45.12 on the upside on Friday, eventually ending the session at $44.75, with a gain of 0.67% or 0.3 points. The heightened volatility saw the trading volume jump to 1,34,23,155 shares. Company has a market cap of $65,745 M.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.